Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. 1987

R de Martin, and B Haendler, and R Hofer-Warbinek, and H Gaugitsch, and M Wrann, and H Schlüsener, and J M Seifert, and S Bodmer, and A Fontana, and E Hofer
Sandoz Forschungsinstitut, Wien, Austria.

Human glioblastoma cells secrete a peptide, termed glioblastoma-derived T cell suppressor factor (G-TsF), which has suppressive effects on interleukin-2-dependent T cell growth. As shown here, complementary DNA for G-TsF reveals that G-TsF shares 71% amino acid homology with transforming growth factor-beta (TGF-beta). In analogy to TGF-beta it is apparently synthesized as the carboxy-terminal end of a precursor polypeptide which undergoes proteolytic cleavage to yield the 112 amino-acid-long mature form of G-TsF. Comparison of the amino-terminal sequence of G-TsF with that of porcine TGF-beta 2 and bovine cartilage-inducing factor B shows complete homology, which indicates that we have cloned the human analogue of these factors. It is tempting to consider a role for G-TsF in tumor growth where it may enhance tumor cell proliferation in an autocrine way and/or reduce immunosurveillance of tumor development.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D005796 Genes A category of nucleic acid sequences that function as units of heredity and which code for the basic instructions for the development, reproduction, and maintenance of organisms. Cistron,Gene,Genetic Materials,Cistrons,Genetic Material,Material, Genetic,Materials, Genetic
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein

Related Publications

R de Martin, and B Haendler, and R Hofer-Warbinek, and H Gaugitsch, and M Wrann, and H Schlüsener, and J M Seifert, and S Bodmer, and A Fontana, and E Hofer
April 1988, European journal of immunology,
R de Martin, and B Haendler, and R Hofer-Warbinek, and H Gaugitsch, and M Wrann, and H Schlüsener, and J M Seifert, and S Bodmer, and A Fontana, and E Hofer
October 1988, International journal of cancer,
R de Martin, and B Haendler, and R Hofer-Warbinek, and H Gaugitsch, and M Wrann, and H Schlüsener, and J M Seifert, and S Bodmer, and A Fontana, and E Hofer
November 1992, Molecular endocrinology (Baltimore, Md.),
R de Martin, and B Haendler, and R Hofer-Warbinek, and H Gaugitsch, and M Wrann, and H Schlüsener, and J M Seifert, and S Bodmer, and A Fontana, and E Hofer
June 1987, The EMBO journal,
R de Martin, and B Haendler, and R Hofer-Warbinek, and H Gaugitsch, and M Wrann, and H Schlüsener, and J M Seifert, and S Bodmer, and A Fontana, and E Hofer
January 1991, Cancer immunology, immunotherapy : CII,
R de Martin, and B Haendler, and R Hofer-Warbinek, and H Gaugitsch, and M Wrann, and H Schlüsener, and J M Seifert, and S Bodmer, and A Fontana, and E Hofer
July 1988, Proceedings of the National Academy of Sciences of the United States of America,
R de Martin, and B Haendler, and R Hofer-Warbinek, and H Gaugitsch, and M Wrann, and H Schlüsener, and J M Seifert, and S Bodmer, and A Fontana, and E Hofer
September 1990, Biochemical and biophysical research communications,
R de Martin, and B Haendler, and R Hofer-Warbinek, and H Gaugitsch, and M Wrann, and H Schlüsener, and J M Seifert, and S Bodmer, and A Fontana, and E Hofer
December 1992, Lymphokine and cytokine research,
R de Martin, and B Haendler, and R Hofer-Warbinek, and H Gaugitsch, and M Wrann, and H Schlüsener, and J M Seifert, and S Bodmer, and A Fontana, and E Hofer
May 1998, The Journal of biological chemistry,
R de Martin, and B Haendler, and R Hofer-Warbinek, and H Gaugitsch, and M Wrann, and H Schlüsener, and J M Seifert, and S Bodmer, and A Fontana, and E Hofer
November 1994, Biochemical and biophysical research communications,
Copied contents to your clipboard!